Alkem Laboratories has officially disclosed the resignation of Dr. Vikas Gupta from his position as Chief Executive Officer & Key Managerial Personnel through a formal regulatory filing on April 24, 2026. The disclosure was made under Regulation 30 of SEBI LODR Regulations to both BSE Limited and National Stock Exchange of India Limited.

Official Regulatory Disclosure

The company filed the resignation disclosure with stock exchanges, providing comprehensive details as required under SEBI regulations. The formal communication was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, and included Dr. Gupta's resignation letter as an annexure.

Resignation Letter Details

In his formal resignation letter dated April 24, 2026, Dr. Gupta expressed gratitude for his tenure and highlighted the company's achievements during his leadership. He emphasized the collective efforts focused on making Alkem a future-ready organization and noted that the foundation built positions the company well for its next chapter of growth.

Leadership Achievements and Strategic Focus

Dr. Gupta outlined key accomplishments during his tenure, including strengthening Alkem's market position and advancing the R&D pipeline. He specifically mentioned navigating the evolving global pharmaceutical landscape and demonstrating resilience unique to Alkem's culture during challenging times.

Transition and Handover Process

Dr. Gupta committed to ensuring a seamless handover of all ongoing strategic initiatives and leadership responsibilities until June 30, 2026. He expressed full confidence in the company's continued growth and success, stating his commitment remains steadfast during the transition period.

Regulatory Compliance

The disclosure complies with SEBI Master Circular bearing No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026. The information is also available on the company's official website at www.alkemlabs.com , ensuring complete transparency with stakeholders and regulatory authorities.

Alkem Laboratories has received an income tax assessment order disputing ₹333.38 crores for the assessment year 2023-24, the pharmaceutical company disclosed under Regulation 30 of SEBI LODR Regulations on 24th April 2026.

Assessment Order Details

The Deputy Commissioner of Income Tax, Central Circle 8(1), Mumbai issued the assessment order dated 13th April 2026 under section 143(3) read with section 144C(3) of the Income Tax Act, 1961. The order was received by the company on 24th April 2026.

Nature of Disputes

The income tax authority has raised two primary issues in the assessment order:

• Section 80IE Deduction: Disallowance of part of deduction claimed under section 80IE of the Income Tax Act, 1961
• Transfer Pricing Adjustments: Additional adjustments related to transfer pricing matters

These adjustments have resulted in the disputed tax amount of ₹333.38 crores being raised by the IT authority.

Financial Impact Assessment

Despite the substantial disputed amount, Alkem Laboratories has clarified that no amount is payable by the company due to the utilization of available Minimum Alternate Tax (MAT) credit. The company has stated there is no material impact on its financial, operational, or other activities due to this order.

Company's Response Strategy

Alkem Laboratories has expressed confidence in its position regarding the disputed assessment. The company believes that the dispute raised in the order is not tenable and maintains that it has adequate factual and legal grounds to substantiate its position. The pharmaceutical manufacturer has indicated its intention to pursue an appeal against the assessment order under applicable laws.

This development follows the company's earlier intimation dated 14th September 2023, suggesting ongoing interactions with tax authorities. The disclosure has been made available on the company's website at www.alkemlabs.com as part of its transparency commitments to stakeholders.